Nancy Lurker's most recent trade in Alkermes plc was a trade of 11,538 Non Qualified Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 20, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Alkermes PLC | Ms. Nancy S. Lurker | Director | 20 May 2026 | 11,538 | 11,538 | - | - | Non Qualified Stock Option (Right to Buy) | ||
| Alkermes PLC | Ms. Nancy S. Lurker | Director | 20 May 2026 | 6,142 | 0 | - | - | Restricted Stock Unit Award | ||
| Alkermes PLC | Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2026 | 6,142 | 19,697 (0%) | 0% | - | Ordinary Shares | |
| Alkermes PLC | Ms. Nancy S. Lurker | Director | 20 May 2026 | 5,409 | 5,409 | - | - | Restricted Stock Unit Award | ||
| Alkermes PLC | Ms. Nancy S. Lurker | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 36.95 per share. | 20 May 2026 | 1,475 | 18,222 (0%) | 0% | 36.9 | 54,501 | Ordinary Shares |
| Collegium pharma Inc | Ms. Nancy S. Lurker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2026 | 8,741 | 26,758 (0%) | 0% | 0 | Common Stock | |
| Collegium pharma Inc | Ms. Nancy S. Lurker | Director | Sale of securities on an exchange or to another person at price $ 35.97 per share. | 13 May 2026 | 4,500 | 18,017 (0%) | 0% | 36.0 | 161,861 | Common Stock |
| Alkermes PLC | Ms. Nancy S. Lurker | Director | 11 Apr 2026 | 3,751 | 3,752 | - | - | Restricted Stock Unit Award | ||
| Alkermes PLC | Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Apr 2026 | 3,751 | 14,456 (0%) | 0% | - | Ordinary Shares | |
| Alkermes PLC | Ms. Nancy S. Lurker | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.36 per share. | 11 Apr 2026 | 901 | 13,555 (0%) | 0% | 33.4 | 30,057 | Ordinary Shares |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2026 | 75,133 | 294,346 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | 06 Jan 2026 | 75,133 | 0 | - | - | Restricted Stock Units | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2026 | 75,133 | 294,346 (0%) | 0% | 0 | - | |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2026 | 75,133 | 294,346 (0%) | 0% | 0 | - | |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | 02 Jan 2026 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 12,666 | 219,213 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | 02 Jan 2026 | 12,666 | 12,667 | - | - | Restricted Stock Units | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 12,666 | 219,213 (0%) | 0% | 0 | - | |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 12,666 | 219,213 (0%) | 0% | 0 | - | |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | Sale of securities on an exchange or to another person at price $ 15.11 per share. | 04 Dec 2025 | 9,300 | 206,547 (0%) | 0% | 15.1 | 140,477 | Common Stock |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | Sale of securities on an exchange or to another person at price $ 15.11 per share. | 04 Dec 2025 | 9,300 | 206,547 (0%) | 0% | 15.1 | 140,477 | - |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | Sale of securities on an exchange or to another person at price $ 15.11 per share. | 04 Dec 2025 | 9,300 | 206,547 (0%) | 0% | 15.1 | 140,477 | - |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | Sale of securities on an exchange or to another person at price $ 14.95 per share. | 26 Nov 2025 | 500 | 215,847 (0%) | 0% | 15.0 | 7,475 | Common Stock |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | Sale of securities on an exchange or to another person at price $ 14.95 per share. | 26 Nov 2025 | 500 | 215,847 (0%) | 0% | 15.0 | 7,475 | - |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | Sale of securities on an exchange or to another person at price $ 14.95 per share. | 26 Nov 2025 | 500 | 215,847 (0%) | 0% | 15.0 | 7,475 | - |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | Sale of securities on an exchange or to another person at price $ 14.95 per share. | 26 Nov 2025 | 200 | 216,347 (0%) | 0% | 15.0 | 2,990 | Common Stock |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | Sale of securities on an exchange or to another person at price $ 14.95 per share. | 26 Nov 2025 | 200 | 216,347 (0%) | 0% | 15.0 | 2,990 | - |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | Sale of securities on an exchange or to another person at price $ 14.95 per share. | 26 Nov 2025 | 200 | 216,347 (0%) | 0% | 15.0 | 2,990 | - |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2025 | 11,111 | 216,547 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | 10 Jul 2025 | 11,111 | 11,112 | - | - | Restricted Stock Units | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2025 | 11,111 | 216,547 (0%) | 0% | 0 | - | |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2025 | 11,111 | 216,547 (0%) | 0% | 0 | - | |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | 02 Jul 2025 | 103,308 | 178,442 | - | - | Stock Option (Right to Buy) | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | 02 Jul 2025 | 103,308 | 272,358 | - | - | Stock Option (Right to Buy) | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | 02 Jul 2025 | 55,000 | 40,000 | - | - | Stock Option (Right to Buy) | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | 02 Jul 2025 | 55,000 | 200,000 | - | - | Stock Option (Right to Buy) | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | 02 Jul 2025 | 31,165 | 0 | - | - | Stock Option (Right to Buy) | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | 02 Jul 2025 | 31,165 | 213,700 | - | - | Stock Option (Right to Buy) | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | 02 Jul 2025 | 27,270 | 49,730 | - | - | Stock Option (Right to Buy) | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | 02 Jul 2025 | 27,270 | 27,270 | - | - | Stock Option (Right to Buy) | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | 02 Jul 2025 | 15,278 | 31,944 | - | - | Stock Option (Right to Buy) | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | 02 Jul 2025 | 15,278 | 34,722 | - | - | Stock Option (Right to Buy) | ||
| Alkermes PLC | Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2025 | 8,013 | 12,629 (0%) | 0% | - | Ordinary Shares | |
| Alkermes PLC | Ms. Nancy S. Lurker | Director | 31 May 2025 | 8,013 | 0 | - | - | Restricted Stock Unit Award | ||
| Alkermes PLC | Ms. Nancy S. Lurker | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.61 per share. | 31 May 2025 | 1,924 | 10,705 (0%) | 0% | 30.6 | 58,894 | Ordinary Shares |
| Alkermes PLC | Ms. Nancy S. Lurker | Director | 21 May 2025 | 13,474 | 13,474 | - | - | Non Qualified Stock Option (Right to Buy) | ||
| Alkermes PLC | Ms. Nancy S. Lurker | Director | 21 May 2025 | 6,142 | 6,142 | - | - | Restricted Stock Unit Award | ||
| Collegium pharma Inc | Ms. Nancy S. Lurker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 9,791 | 22,517 (0%) | 0% | 0 | Common Stock | |
| Alkermes PLC | Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Apr 2025 | 3,752 | 5,517 (0%) | 0% | - | Ordinary Shares | |
| Alkermes PLC | Ms. Nancy S. Lurker | Director | 11 Apr 2025 | 3,752 | 7,503 | - | - | Restricted Stock Unit Award | ||
| Alkermes PLC | Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Apr 2025 | 2,323 | 2,323 (0%) | 0% | - | Ordinary Shares | |
| Alkermes PLC | Ms. Nancy S. Lurker | Director | 11 Apr 2025 | 2,323 | 0 | - | - | Restricted Stock Unit Award | ||
| Alkermes PLC | Ms. Nancy S. Lurker | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.00 per share. | 11 Apr 2025 | 901 | 4,616 (0%) | 0% | 27 | 24,327 | Ordinary Shares |
| Alkermes PLC | Ms. Nancy S. Lurker | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.00 per share. | 11 Apr 2025 | 558 | 1,765 (0%) | 0% | 27 | 15,066 | Ordinary Shares |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | 09 Feb 2025 | 20,000 | 0 | - | - | Restricted Stock Units | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2025 | 20,000 | 205,436 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2025 | 20,000 | 205,436 (0%) | 0% | 0 | - | |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2025 | 20,000 | 205,436 (0%) | 0% | 0 | - | |
| Collegium pharma Inc | Ms. Nancy S. Lurker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 12,726 | 12,726 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 75,134 | 185,436 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | 03 Jan 2025 | 75,134 | 75,133 | - | - | Restricted Stock Units | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 75,134 | 185,436 (0%) | 0% | 0 | - | |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 75,134 | 185,436 (0%) | 0% | 0 | - | |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | 03 Jan 2025 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | 03 Jan 2025 | 12,667 | 25,333 | - | - | Restricted Stock Units | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 12,667 | 110,302 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 12,667 | 110,302 (0%) | 0% | 0 | - | |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 12,667 | 110,302 (0%) | 0% | 0 | - | |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | Purchase of securities on an exchange or from another person at price $ 7.88 per share. | 16 Aug 2024 | 3,173 | 97,635 (0%) | 0% | 7.9 | 25,003 | Common Stock |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | 26 Jul 2024 | 56,350 | 169,050 | - | - | Stock Option (Right to Buy) | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | 26 Jul 2024 | 56,350 | 281,750 | - | - | Stock Option (Right to Buy) | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | 26 Jul 2024 | 30,000 | 145,000 | - | - | Stock Option (Right to Buy) | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | 26 Jul 2024 | 30,000 | 95,000 | - | - | Stock Option (Right to Buy) | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | 26 Jul 2024 | 26,713 | 182,535 | - | - | Stock Option (Right to Buy) | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | 26 Jul 2024 | 26,713 | 31,165 | - | - | Stock Option (Right to Buy) | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | 26 Jul 2024 | 16,666 | 16,666 | - | - | Stock Option (Right to Buy) | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | 26 Jul 2024 | 16,666 | 50,000 | - | - | Stock Option (Right to Buy) | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | 26 Jul 2024 | 1,558 | 0 | - | - | Stock Option (Right to Buy) | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director | 26 Jul 2024 | 1,558 | 74,800 | - | - | Stock Option (Right to Buy) | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director, Executive Vice Chair | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2024 | 11,111 | 94,462 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director, Executive Vice Chair | 10 Jul 2024 | 11,111 | 22,223 | - | - | Restricted Stock Units | ||
| Alkermes PLC | Ms. Nancy S. Lurker | Director | 31 May 2024 | 17,492 | 17,492 | - | - | Non Qualified Stock Option (Right to Buy) | ||
| Alkermes PLC | Ms. Nancy S. Lurker | Director | 31 May 2024 | 8,013 | 8,013 | - | - | Restricted Stock Unit Award | ||
| Alkermes PLC | Ms. Nancy S. Lurker | Director | 11 Apr 2024 | 22,103 | 22,103 | - | - | Non Qualified Stock Option (Right to Buy) | ||
| Alkermes PLC | Ms. Nancy S. Lurker | Director | 11 Apr 2024 | 11,255 | 11,255 | - | - | Restricted Stock Unit Award | ||
| Alkermes PLC | Ms. Nancy S. Lurker | Director | 11 Apr 2024 | 4,833 | 4,833 | - | - | Non Qualified Stock Option (Right to Buy) | ||
| Alkermes PLC | Ms. Nancy S. Lurker | Director | 11 Apr 2024 | 2,323 | 2,323 | - | - | Restricted Stock Unit Award | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Feb 2024 | 74,681 | 126,889 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Feb 2024 | 74,681 | 83,351 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director, Executive Vice Chair | 09 Feb 2024 | 20,000 | 20,000 | - | - | Restricted Stock Units | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director, Executive Vice Chair | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 20,000 | 155,441 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director, Executive Vice Chair | 09 Feb 2024 | 17,534 | 0 | - | - | Restricted Stock Units | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director, Executive Vice Chair | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 17,534 | 172,975 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director, Executive Vice Chair | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 7,962 | 165,013 (0%) | 0% | 28.8 | 229,306 | Common Stock |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director, Executive Vice Chair | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 6,981 | 158,032 (0%) | 0% | 28.8 | 201,053 | Common Stock |
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director, Executive Vice Chair | 09 Feb 2024 | 5,000 | 125,000 | - | - | Stock Option (Right to Buy) | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director, Executive Vice Chair | 09 Feb 2024 | 5,000 | 115,000 | - | - | Stock Option (Right to Buy) | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director, Executive Vice Chair | 09 Feb 2024 | 4,452 | 155,822 | - | - | Stock Option (Right to Buy) | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director, Executive Vice Chair | 09 Feb 2024 | 4,452 | 57,878 | - | - | Stock Option (Right to Buy) | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director, Executive Vice Chair | 09 Feb 2024 | 3,116 | 1,558 | - | - | Stock Option (Right to Buy) | ||
| EyePoint Pharma Inc | Ms. Nancy S. Lurker | Director, Executive Vice Chair | 09 Feb 2024 | 3,116 | 73,242 | - | - | Stock Option (Right to Buy) |